Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Side Effects Clear all
Completed Phase 2 Interventional

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

NCT01539343
View directory record Official record
Conditions
Infection
Interventions
Antimicrobial Solution
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting Not applicable Interventional

The Multicentre Selective Lymphadenectomy Trial - 3

NCT07049276
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III
Interventions
Index lymph node resection, Therapeutic lymph node dissection
Procedure
Lead sponsor
Melanoma Institute Australia
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting No phase listed Observational

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer

NCT05096338
View directory record Official record
Conditions
Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
Interventions
Social Determinants of Health
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting No phase listed Observational

Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient

NCT03839784
View directory record Official record
Conditions
Cognitive Decline, Cognitive Change, Cognitive Impairment, Postoperative Delirium, Anesthesia; Reaction, Anesthesia; Adverse Effect
Interventions
Neurocognition Interventions
Combination Product
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

NCT00198419
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 23, 2026, 2:07 PM EDT
Not listed No phase listed Observational

A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

NCT04571398
View directory record Official record
Conditions
Cancer
Interventions
ApricityRx mobile application
Other
Lead sponsor
Apricity Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting No phase listed Observational

Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients

NCT02772367
View directory record Official record
Conditions
Breast Cancer
Interventions
skin punch biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

NCT05721729
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
Mizagliflozin, Placebo
Drug
Lead sponsor
Vogenx, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting No phase listed Observational

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT06151730
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Diabetes Prevention Program

NCT00004992
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Glucose Intolerance
Interventions
Intensive lifestyle, Metformin, Placebo
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years and older
Enrollment
3,234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2001
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

NCT06500429
View directory record Official record
Conditions
Overweight and Obesity, Healthy
Interventions
NG101, Placebo, Semaglutide Injectable Product
Drug
Lead sponsor
Neurogastrx, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device for the Appearance of Cellulite in Adult Participants

NCT05664581
View directory record Official record
Conditions
Cellulite
Interventions
Rapid Acoustic Pulse
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 23, 2026, 2:07 PM EDT
Recruiting Phase 1Phase 2 Interventional

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

NCT03934905
View directory record Official record
Conditions
Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions
sulforaphane, Placebo Oral Tablet
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional Results available

Skin Care for Cancer Patients: A Product Satisfaction Survey

NCT00871429
View directory record Official record
Conditions
Skin Toxicity
Interventions
Lindi skin care products
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Health Literacy Multi-media Study

NCT02999529
View directory record Official record
Conditions
Cancer
Interventions
Educational Video
Other
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Diminish Chemotherapy Related Side Effects Through Patient Education

NCT04694794
View directory record Official record
Conditions
Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity, Chemotherapy Effect
Interventions
Educational Brochure
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 23, 2026, 2:07 PM EDT
Active, not recruiting No phase listed Observational

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

NCT04305613
View directory record Official record
Conditions
Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions
Chemoradiation
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

NCT00075868
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions
octreotide acetate, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
112
States / cities
Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes

NCT01531088
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Active medication monitoring
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 23, 2026, 2:07 PM EDT
Withdrawn Phase 4 Interventional

Is Myopathy Part of Statin Therapy (IMPOSTER-16)

NCT00127335
View directory record Official record
Conditions
Myopathic Conditions
Interventions
cellulose placebo vs. atorvastatin
Drug
Lead sponsor
Scripps Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 4 Interventional

Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids

NCT01378689
View directory record Official record
Conditions
Adverse Effect of Glucocorticoids and Synthetic Analogues, Osteoporosis, Rheumatoid Arthritis
Interventions
Storytelling online video
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
4,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional

Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

NCT00154141
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Fibrin sealant (FS2)
Drug
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Jacksonville, Florida • Miami, Florida • Springfield, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Oct 23, 2026, 2:07 PM EDT